<DOC>
	<DOCNO>NCT01956747</DOCNO>
	<brief_summary>The purpose study ass whether presence Myelodysplastic Syndrome ( MDS ) , Idiopathic Cytopenia Undetermined Significance ( ICUS ) Idiopathic Dysplasia Undetermined Significance ( IDUS ) , correlate treatment intensity clinical outcome older patient advanced malignancy receive palliative chemotherapy . We study relation sarcopenia , comprehensive geriatric assessment en pharmacokinetics treatment relate toxicity well . We hypothesize standardized flow cytometry test determine bone marrow capacity , Comprehensive Geriatric Assessment and/or measurement human body composition computerize tomography provide accurate tool optimize treatment strategy elderly patient advanced malignancy .</brief_summary>
	<brief_title>Optimization Systemic Treatment Strategies Elderly Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Age ≥ 70 year Diagnosis advance cancer colorectum , breast prostate Standard first line palliative treatment cytotoxic agent start ( Folfox , Xelox , capecitabine , paclitaxel docetaxel ) Estimated life expectancy ≥ 3 month Able give inform consent WHO performance status ≤ 2 Absence psychological , familial , sociological geographical condition potentially hamper compliance treatment followup schedule ; condition assess patient registration trial No severe medical psychiatric condition judgment investigator render patient inappropriate inclusion study . Before patient registration , write informed consent must give documented ICH/EUCGCP , national/local regulatory requirement local rule follow institution Presence cytopenia due iron , vitamin B12 folic acid deficiency hemolysis , unless adequately supplement . Creatinine clearance ≤ 30 ml/min Serum AST ALT ≥ 2.5 x ULN , case liver metastases serum AST ALT ≥ 5 x ULN In case therapy Docetaxel/Paclitaxel serum bilirubin ≥ 1.5 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>